FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.02 USD
-0.08 (-1.33%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Jay R. Luly Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.enanta.comexchange
NASDAQ
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
CIK
0001177648
ISIN
US29251M1062
CUSIP
29251M106
Address
500 Arsenal Street
Phone
617 607 0800
Country
US
Employee
145
IPO Date
Mar 21, 2013
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ENTA Financial Summary
CIK
0001177648
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
29251M106
ISIN
US29251M1062
Country
US
Price
6.02
Beta
0.57
Volume Avg.
280.98k
Market Cap
127.59M
Shares
-
52-Week
5.7-17.8
DCF
-7.91
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.1
P/B
-
Website
https://www.enanta.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ENTA News
It looks like there's no news available.
